Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer

Lili Wu, Zikai Wang, Gang Sun, Lihua Peng, Zhongsheng Lu, Bin Yan, Kun Huang, Yunsheng Yang, Lili Wu, Zikai Wang, Gang Sun, Lihua Peng, Zhongsheng Lu, Bin Yan, Kun Huang, Yunsheng Yang

Abstract

This study aimed to investigate the intestinal microbiota in duodenal ulcer (DU) patients, effects of proton pump inhibitors,clarithromycin and amoxicillin, PCA) for Helicobacter pylori (H. pylori) and Bacillus subtilis and Enterococcus faecium (BSEF) on intestinal microbiota. DU patients were randomly assigned to receive either PCA (group TT) or PCA plus BSEF(group TP). The fecal microbiome was conducted using high throughput 16S rDNA gene and internal transcribed spacer sequencings. The diversity and abundance of intestinal bacteria in the DU were significantly lower than health check control (HC) group. In the TT group, the abundance and diversity of both intestinal bacteria and fungi decreased after PCA treatment, compared with those before treatment, whereas in the TP group no obvious changes were observed. In the TT group at all the time points, both the intestinal bacteria and fungi were different from those in the HC group. However, in the TP group, at 10w the bacterial flora abundance was close to that in the HC group. The results indicate that anti- H. pylori treatment induced significant decrease in the diversity of intestinal microbiota, while the combined therapy supplemented with BSEF could protect and restore the intestinal microbiota.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Gastric pH value before and after treatment.
Figure 2
Figure 2
Comparison of OTUs from the 2 groups at the species and genus levels.
Figure 3
Figure 3
PCoA analysis (blue denotes the HC group and red denotes the DU group).
Figure 4
Figure 4
Unweighted UniFra distance clustering tree of samples.
Figure 5
Figure 5
Comparison of OTUs of the 2 groups of at the species and genus level.
Figure 6
Figure 6
PCoA analysis (blue represents the HC group, and red represents the DU group).
Figure 7
Figure 7
Clustering tree.
Figure 8
Figure 8
OTUs at different time points before and after treatment.
Figure 9
Figure 9
Abundance changes of bacterial phyla in the TT group before and after treatment.
Figure 10
Figure 10
Abundance changes of bacterial phyla in the TP group before and after treatment.
Figure 11
Figure 11
OTUs at different time points before and after treatment.

References

    1. Malfertheiner P, et al. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–664. doi: 10.1136/gutjnl-2012-302084.
    1. Asaka M, et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J. Gastroenterol. 2003;38:339–347. doi: 10.1007/s005350300061.
    1. Vesper BJ, et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84–89. doi: 10.2174/138920009787048392.
    1. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334–339. doi: 10.1056/NEJMcp011603.
    1. Yap TW, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PLoS One. 2016;11:e0151893. doi: 10.1371/journal.pone.0151893.
    1. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12:309–316. doi: 10.1111/j.1523-5378.2007.00516.x.
    1. Armuzzi A, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001;15:163–169. doi: 10.1046/j.1365-2036.2001.00923.x.
    1. De Luca L, et al. Measuring dyspepsia: a new severity index validated in Bologna. Dig Liver Dis. 2004;36:806–810. doi: 10.1016/j.dld.2004.07.010.
    1. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261–5267. doi: 10.1128/AEM.00062-07.
    1. Caporaso JG, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–4522. doi: 10.1073/pnas.1000080107.
    1. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996–998. doi: 10.1038/nmeth.2604.
    1. Caporaso JG, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336. doi: 10.1038/nmeth.f.303.
    1. Zhou L, et al. A comparative study of sequential therapy and standard riple therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial. Am J Gastroenterol. 2014;109:535–541. doi: 10.1038/ajg.2014.26.
    1. Duman DG, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2005;17:1357–1361. doi: 10.1097/00042737-200512000-00015.
    1. Wang KY, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004;80:737–741. doi: 10.1093/ajcn/80.3.649.
    1. Kim MN, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008;13:261–268. doi: 10.1111/j.1523-5378.2008.00601.x.
    1. Chen X, et al. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci. 2012;77:M9–14. doi: 10.1111/j.1750-3841.2011.02498.x.
    1. Dai C, Zheng CQ, Jiang M. Efficacy of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:814–815. doi: 10.1097/MCG.0b013e318298a32c.
    1. Park SK, et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology. 2007;54:2032–2036.
    1. Guerre J, Vedel G, Gaudric M, Paul G, Cornuau J. Bacterial flora in gastric juice taken at endoscopy in 93 normal subjects. Pathol Biol (Paris) 1986;34:57–60.
    1. Perez-Cobas AE, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013;62:1591–1601. doi: 10.1136/gutjnl-2012-303184.
    1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–2379. doi: 10.1056/NEJMra1600266.
    1. Kahrstrom CT, Pariente N, Weiss U. Intestinal microbiota in health and disease. Nature. 2016;535:47. doi: 10.1038/535047a.
    1. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;16:312297.
    1. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544–545. doi: 10.1126/science.aad9358.
    1. Jackson MA, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756. doi: 10.1136/gutjnl-2015-310861.
    1. Imhann F, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748. doi: 10.1136/gutjnl-2015-310376.
    1. Oh B, et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: Randomized Controlled Trial. Helicobacter. 2016;21:165–174. doi: 10.1111/hel.12270.
    1. Buhling A, Radun D, Muller WA, Malfertheiner P. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther. 2001;15:1445–1452. doi: 10.1046/j.1365-2036.2001.01033.x.
    1. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J. Antimicrob Chemother. 1999;44:629–640. doi: 10.1093/jac/44.5.629.
    1. Lou JG, Chen J, Huang XL, Zhao ZY. Changes in the intestinal microflora of children with Helicobacter pylori infection and after Helicobacter pylori eradication therapy. Chin Med J (Engl) 2007;120:929–931. doi: 10.1097/00029330-200705020-00014.
    1. Sheu BS, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16:1669–1675. doi: 10.1046/j.1365-2036.2002.01335.x.
    1. Tompkins TA, Hagen KE, Wallace TD, Fillion-Forte V. Safety evaluation of two bacterial strains used in Asian probiotic products. Can J Microbiol. 2008;54:391–400. doi: 10.1139/W08-022.
    1. Pinchuk IV, et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45:3156–3161. doi: 10.1128/AAC.45.11.3156-3161.2001.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅